The Efficacy and Safety of Lurasidone in Adolescent Patients With Schizophrenia: A 6-Week, Double-Blind, Placebo-Controlled, Multicenter Study

被引：0

作者：

Correll, Christoph U. ^{[1
]}

Goldman, Robert ^{[1
]}

Silva, Robert ^{[1
]}

Cucchiaro, Josephine ^{[1
]}

Deng, Ling ^{[1
]}

Loebel, Antony ^{[1
]}

机构：

[1] Sunov Pharmaceut Inc, Ft Lee, NJ USA

来源：

NEUROPSYCHOPHARMACOLOGY | 2016年 / 41卷

关键词：

Schizophrenia; Lurasidone; Adolescence; Psychopharmacology;

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

W215

引用

页码：S597 / S598

页数：2

共 50 条

[1] THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY
Goldman, Robert S.
Findling, Robert L.
Silva, Robert M.
Cucchiaro, Josephine B.
Deng, Ling
Loebel, Antony
[J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S163 - S164
[2] The efficacy of lurasidone on PANSS subscales in adolescent patients with schizophrenia: Results from a 6-week, double-blind, placebo-controlled, multicenter study
Correll, C.
Goldman, R.
Cucchiaro, J.
Deng, L.
Loebel, A.
[J]. EUROPEAN PSYCHIATRY, 2017, 41 : S90 - S91
[3] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
Iyo, Masaomi
Ishigooka, Jun
Nakamura, Masatoshi
Sakaguchi, Reiko
Okamoto, Keisuke
Mao, Yongcai
Tsai, Joyce
Fitzgerald, Alison
Nosaka, Tadashi
Higuchi, Teruhiko
[J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (07) : 227 - 235
[4] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
Iyo, Masaomi
Ishigooka, Jun
Nakamura, Masatoshi
Sakaguchi, Reiko
Okamoto, Keisuke
Mao, Yongcai
Tsai, Joyce
Fitzgerald, Alison
Nosaka, Tadashi
Higuchi, Teruhiko
[J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, : 227 - 235
[5] The efficacy and safety of lurasidone in adolescent patients with schizophrenia: Results of functional and quality of life measures from a 6-week, double-blind, placebo-controlled study
Findling, R.
Goldman, R.
Cucchiaro, J.
Deng, L.
Loebel, A.
[J]. EUROPEAN PSYCHIATRY, 2017, 41 : S94 - S94
[6] Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
Iwata, Nakao
Ishigooka, Jun
Kim, Won-Hyoung
Yoon, Bo-Hyun
Lin, Shih-Ku
Sulaiman, Ahmad Hatim
Cosca, Rowena
Wang, Lina
Suchkov, Yury
Agarkov, Alexey
Watabe, Kei
Matsui, Tomohito
Sato, Takayuki
Inoue, Yoshifumi
Higuchi, Teruhiko
Correll, Christoph U.
Kane, John M.
[J]. SCHIZOPHRENIA RESEARCH, 2020, 215 : 408 - 415
[7] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
Calisti, F.
Costamagna, I.
Hsu, J.
Tocco, M.
Pikalov, A.
Goldman, R.
[J]. EUROPEAN PSYCHIATRY, 2021, 64 : S166 - S166
[8] A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia
Haas, Magali
Unis, Alan S.
Armenteros, Jorge
Copenhaver, Margaret D.
Quiroz, Jorge A.
Kushner, Stuart F.
[J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (06) : 611 - 621
[9] Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
Goldman, Robert
Loebel, Antony
Cucchiaro, Josephine
Deng, Ling
Findling, Robert L.
[J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 516 - 525
[10] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: pooled analysis of double-blind, placebo-controlled 6-week studies
Costamagna, I.
Calisti, F.
Hsu, J.
Tocco, M.
Pikalov, A.
Goldman, R.
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S473 - S474

← 1 2 3 4 5 →